CASBF - Sino Biopharmaceutical: Investing In China's COVID-19 Vaccine While Sinovac Remains Halted

• Sinovac Biotech has developed a successful COVID-19 vaccine, CoronaVac, directly competing with two Chinese rivals, Pfizer, AstraZeneca, Moderna and Russia's Sputnik V.
• Nasdaq and Hong Kong-listed partner Sino Biopharm providing $515 million funding for 15.03% equity stake in Sinovac. Sinovac's Nasdaq listing currently still halted after attack from activist shareholders.
• Way forward unclear, but SEC seemingly supporting Sinovac's version of events. In the meantime, CoronaVac has been approved and currently in use in several countries.
• Best opportunity to invest in CoronaVac's success is through Sino Biopharm.

For further details see: